Abstract
Disease progression of human immunodeficiency virus type 1 (HIV-1) is associated with immune activation. Activation indices are higher during coinfection of hepatitis C virus (HCV) and HIV. The effect of immune activation on interferon α (IFN-α) therapy response is unknown. We evaluated soluble CD14 (sCD14) and natural killer (NK)-cell subsets at baseline, and during pegIFN-α2a/ribavirin therapy in HCV-HIV coinfection. The sCD14 level increased during therapy. Baseline sCD14 positively correlated with baseline HCV level and CD16(+)56(-) NK-cell frequency, and both sCD14 and CD16(+)56(-) NK cells correlated negatively with magnitude of HCV decline. IL28B genotype was associated with therapy response but not sCD14 or CD16(+)56(-) NK frequency. Markers of innate immune activation predict poor host response to IFN-α-based HCV therapy during HCV-HIV coinfection.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antiviral Agents / therapeutic use*
-
CD56 Antigen / metabolism
-
Coinfection
-
Drug Therapy, Combination
-
Female
-
Genotype
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV-1*
-
Hepatitis C / complications
-
Hepatitis C / drug therapy*
-
Humans
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / therapeutic use
-
Killer Cells, Natural / immunology*
-
Killer Cells, Natural / metabolism
-
Lipopolysaccharide Receptors / metabolism
-
Male
-
Polyethylene Glycols / administration & dosage
-
Polyethylene Glycols / therapeutic use
-
Receptors, IgG / metabolism
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / therapeutic use
-
Ribavirin / therapeutic use
Substances
-
Antiviral Agents
-
CD56 Antigen
-
Interferon-alpha
-
Lipopolysaccharide Receptors
-
NCAM1 protein, human
-
Receptors, IgG
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2a